Review anchor
Acetylcholinesterase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Acetylcholinesterase
CHEMBL220
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Acetylcholinesterase as ChEMBL target CHEMBL220, mapped to UniProt P22303. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL220
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22303
Acetylcholinesterase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Acetylcholinesterase matters
Acetylcholinesterase is reviewed as Acetylcholinesterase (UniProt P22303); Acetylcholinesterase shows approved-linked disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 67 approved drugs, 10938 compounds, and 2330 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Acetylcholinesterase
Acetylcholinesterase Sequence length is 614 aa.
Review this target as Acetylcholinesterase, mapped to UniProt P22303. Sequence length is 614 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P22303
Protein
Disease context
Alzheimer disease
Acetylcholinesterase shows approved-linked disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BENZGALANTAMINE GLUCONATE, DONEPEZIL HYDROCHLORIDE, GALANTAMINE HYDROBROMIDE.
Start review with Alzheimer disease because it currently carries approved-linked support. Linked drugs include BENZGALANTAMINE GLUCONATE, DONEPEZIL HYDROCHLORIDE, GALANTAMINE HYDROBROMIDE, HUPERZINE A. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
4 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 67 approved drugs, 10938 compounds, and 2330 assays for this target. The dominant activity type is IC50. CHEMBL3585779 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL3585779 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
67 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Acetylcholinesterase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P22303, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why Alzheimer disease is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
10938
Total Compounds
2330
Total Assays
67
Approved Drugs
IC50: 9692.0, KI: 1904.0, EC50: 63.0, KD: 295.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3585779
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL4205425
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL489454
|
10.9 | Ki | — |
|
|
No preferred name
CHEMBL4205954
|
10.9 | IC50 | — |
|
|
No preferred name
CHEMBL4209803
|
10.9 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
NEOSTIGMINE METHYLSULFATE
CHEMBL211471
|
2013 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
RASAGILINE
CHEMBL887
|
2005 |
|
|
SERTACONAZOLE
CHEMBL1201196
|
2003 |
|
|
ALFUZOSIN
CHEMBL709
|
2003 |
|
|
MEMANTINE
CHEMBL807
|
2002 |
|
|
GALANTAMINE
CHEMBL659
|
2001 |
|
|
RIVASTIGMINE
CHEMBL636
|
1998 |
|
|
RALOXIFENE
CHEMBL81
|
1997 |
|
|
DONEPEZIL HYDROCHLORIDE
CHEMBL1678
|
1996 |
|
|
DONEPEZIL
CHEMBL502
|
1996 |
|
|
IRINOTECAN
CHEMBL481
|
1996 |
|
|
TACRINE
CHEMBL95
|
1993 |
|
|
TACRINE HYDROCHLORIDE
CHEMBL1677
|
1993 |
|
|
FLUOXETINE
CHEMBL41
|
1987 |
|
|
RANITIDINE
CHEMBL1790041
|
1983 |
|
|
ETHOPROPAZINE
CHEMBL1206
|
1982 |
|
|
DYCLONINE
CHEMBL1201217
|
1982 |
|
|
DECAMETHONIUM BROMIDE
CHEMBL1134
|
1982 |
|
|
ISOFLUROPHATE
CHEMBL1025
|
1957 |
|
|
PYRIDOSTIGMINE BROMIDE
CHEMBL812
|
1955 |
|
|
METHOXSALEN
CHEMBL416
|
1954 |
|
|
EDROPHONIUM CHLORIDE
CHEMBL1128
|
1951 |
|
|
PROCAINAMIDE
CHEMBL640
|
1950 |
|
|
BERBERINE
CHEMBL295124
|
— |
Source Header